Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA classifies dressings containing pDADMAC as Class II

This article was originally published in RAJ Devices

Executive Summary

The US Food and Drug Administration is classifying wound dressings that contain the additive poly (diallyl dimethyl ammonium chloride) as Class II devices and has issued a guidance document on special controls that must be followed by manufacturers intending to market such products1-3.

You may also be interested in...



Latest EU Filings Include A First For BeiGene

Potential treatments from BeiGene, AstraZeneca, Bayer and Cancer Prevention Pharmaceuticals are under review at the European Medicines Agency.

Australia Takes Just Five Days To Approve Remdesivir For COVID-19

The Therapeutic Goods Administration’s provisional approval for Gilead Sciences’ drug comes with a number of post-marketing obligations for the company.

Improved EU Patient Access & Reimbursement On The Cards For Translarna

Some reimbursement agencies in Europe have been misinterpreting Translarna’s label and stopping access to the drug for boys with Duchenne muscular dystrophy who have been taking it but whose disease has progressed, PTC says.

UsernamePublicRestriction

Register

LL1133060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel